Uchiyama T
Department of Internal Medicine, Faculty of Medicine, Kyoto University, Japan.
Blood Rev. 1988 Dec;2(4):232-8. doi: 10.1016/0268-960x(88)90012-4.
Adult T-cell leukemia (ATL) is a leukemia caused by a monoclonal expansion of HTLV-I-infected T-cells expressing a CD4 antigen. The clinical features of ATL include lymphadenopathy, hepatosplenomegaly, frequent skin lesions, hypercalcemia and a rapidly fatal course. The cell surface phenotype, cytogenetics and functions of leukemic cells are described in association with various clinical manifestations and HTLV-I infection. Leukemic cells constitutively express the p55 (Tac antigen) subunit of the interleukin-2 (IL-2) receptor. Its association with the function of HTLV-I gene products and its possible role in the leukemogenesis of ATL are discussed. Finally, the potential of some therapeutic agents which may selectively eliminate the Tac-expressing leukemic cells in vitro are described, and these may provide an improvement over currently ineffective combination chemotherapy.
成人T细胞白血病（ATL）是一种由感染人类T淋巴细胞病毒I型（HTLV-I）且表达CD4抗原的T细胞单克隆扩增引起的白血病。ATL的临床特征包括淋巴结病、肝脾肿大、频繁的皮肤病变、高钙血症以及快速致死的病程。白血病细胞的细胞表面表型、细胞遗传学和功能与各种临床表现及HTLV-I感染相关。白血病细胞组成性表达白细胞介素-2（IL-2）受体的p55（Tac抗原）亚基。文中讨论了其与HTLV-I基因产物功能的关联及其在ATL白血病发生中的可能作用。最后，描述了一些可能在体外选择性清除表达Tac的白血病细胞的治疗药物的潜力，这些药物可能比目前无效的联合化疗有所改进。
